MEASURES TOTAL RETINAL AND LAYER THICKNESS FOR THE FOLLOWING LAYERS:
Retinal Nerve Fiber Layer (RNFL; Ganglion Cell Layer (GCL) + Inner Plexiform Layer (IPL); Inner Nuclear Layer (INL) + Outer Plexiform Layer (OPL); Outer Nuclear Layer (ONL); Photoreceptor (PR) + Retinal Pigment Epithelium (RPE; and Choriocapillaris (CC) + Choroidal Stroma (CS).
Fluid and layer segmentation are CE-marked in the E.U. Research Use Only in other jurisdictions.
Healthcare data is largely underutilized today. In general, an overwhelming majority of data (80%) is unstructured and inaccessible. Data within a network is a complex problem - in multiple locations, as multiple formats and within multiple systems that are closed and do not interact with each other. Any effort to extract insights from data takes significant investment of resources and effort, making it impractical for the majority of clinics. As a result, valuable data is unused to improve decisions, limiting improvement of patient outcomes.
Unlocking knowledge from structured data can help establish best clinical practices, personalize treatment or advance new research and clinical studies. Within Discovery CORE, tools are at your fingertips to foster innovation and aggregate collaborative efforts around your data for best practices.
RetinAI Discovery is a CE-marked medical device according to the Medical Devices Regulation (EU) 2017/745
and the AI models are CE-marked devices according to Medical Devices Directive 93/42/EEC
RetinAI Discovery® is a 510(k) FDA Cleared medical device in US.
RetinAI Discovery® and Retinai® are both trademarks of RetinAI Medical AG.
Discovery and AI Models are CE-Marked medical devices since April 2020 & December 2020 respectively.